Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive

Norwood, MA 02062

 

April 30, 2020

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:Corbus Pharmaceuticals Holdings, Inc. (the “Company”)

Registration Statement on Form S-3, as amended (File No. 333-237588)

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on May 1, 2020, or as soon as practicable thereafter.

 

Please call Michael J. Lerner of Lowenstein Sandler LLP at (973) 597-6394 to confirm the effectiveness of the Registration Statement or with any questions.

 

[Signature page follows.]

 

 
 

 

U.S. Securities and Exchange Commission

April 30, 2020

Page 2

 

  Very truly yours,
     
  CORBUS PHARMACEUTICALS
  HOLDINGS, INC.
     
  By: /s/ Sean Moran                    
  Name: Sean Moran
  Title: Chief Financial Officer

 

-2-